Supply Chain Intelligence

Citius Pharmaceuticals, Inc. Supply Chain

CTXR supply chain intelligence for Citius Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CTXR ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
6Customers
3Debt Items
20Related Chains

Citius Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
BIORASI-LLC BIORASI-LLC 92% In May 2022, the Company selected Biorasi, LLC ("Biorasi"), a global clinical research organization ("CRO"), to help expand the Company's Phase 3 Mino-Lok trial by implementing additional sites outsi…
CTOR Citius Oncology, Inc. 92% Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR graph: olution in Phase 3 clinical development, which if approved, would be used to treat catheter-related bloodstream infec…
CTOR Citius Oncology, Inc. 92% olution in Phase 3 clinical development, which if approved, would be used to treat catheter-related bloodstream infections, and is expected to be amortized on a straight-line basis over a period of c…
H-C-WAINWRIGHT-AND-CO-LLC H-C-WAINWRIGHT-AND-CO-LLC 90% H.C. Wainwright and Co., LLC ("Wainwright") acted as the Company's exclusive placement agent in connection with the Offer
INTEGRIS-PHARMA-S-A INTEGRIS-PHARMA-S-A 90% On October 7, 2025, Citius Oncology entered into an exclusive distribution agreement with Integris Pharma S.A
ER-KIM ER-KIM 85% On February 11, 2026, Citius Oncology announced an exclusive distribution agreement with Uniphar
UNIPHAR UNIPHAR 85% On February 11, 2026, Citius Oncology announced an exclusive distribution agreement with Uniphar
MCK McKesson Corporation 72% Reciprocal relationship from MCK graph: Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect…
MCK McKesson Corporation 72% adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…

Citius Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
CTOR Citius Oncology, Inc. 72% s, NoveCite had to maintain Novellus’s ownership at % by issuing additional shares to Novellus. In July 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). In this transact…
CTOR Citius Oncology, Inc. 72% Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR graph: Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR graph: Reciprocal relationship from CTOR g…
MCK McKesson Corporation 72% adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
MCK McKesson Corporation 72% Reciprocal relationship from MCK graph: Reciprocal relationship from CTXR graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CTXR graph: adds the risk of import restrictions,…
DIAGNOSIS-RELATED-GROUP DIAGNOSIS-RELATED-GROUP 62% adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
REPORT-CITIUS-PHARMACEUTICALS-INC REPORT-CITIUS-PHARMACEUTICALS-INC 62% error to previously issued financial statements. ☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation rec…

Citius Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CTXR-DEBT Debt stack $1.8M 90% Market cache reports total debt of $1.8M.
CTXR-DEBT-8927 Warrants outstanding: 5142858 90% xbrl warrant detail from xbrl 2025-09-10.
CTXR-DEBT-8928 Xbrl Convertible 90% xbrl convertible detail from xbrl 2016-09-30.

Citius Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Citius Pharmaceuticals, Inc..

Citius Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
CTXR-OWNER-ARMISTICE-CAPITAL-LLC ARMISTICE CAPITAL, LLC 90% 13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 15 tracked holders.

Citius Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MCK McKesson Corporation 100.00 1 ['customer', 'supplier']
EMMA Emmaus Life Sciences, Inc. 50.00 2
COR Cencora, Inc. 50.00 2
CHRS Coherus Oncology, Inc. 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
AMPH Amphastar Pharmaceuticals, Inc. 50.00 2
SUPN Supernus Pharmaceuticals, Inc. 50.00 2
ADCT ADC Therapeutics SA 50.00 2
CAH Cardinal Health, Inc. 50.00 2
CLH Clean Harbors, Inc. 50.00 2
HCA HCA Healthcare, Inc. 50.00 2
APO-PA Apollo Global Management, Inc. 50.00 2
ARDX Ardelyx, Inc. 50.00 2
HLNCF Haleon plc 50.00 2
VTRS Viatris Inc. 50.00 2
CRM Salesforce, Inc. 50.00 2
GILD Gilead Sciences, Inc. 50.00 2
HALO Halozyme Therapeutics, Inc. 50.00 2
GRDN Guardian Pharmacy Services, Inc. 50.00 2
HLN Haleon plc 50.00 2
View CTXR supply chain intel →

Explore the full interactive supply chain map for Citius Pharmaceuticals, Inc..

Open CTXR supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map